API Process Development - メーカー・企業と業務用製品 | イプロスものづくり

[Column] Contributing to Efficient Active Pharmaceutical Ingredient Process Development by Utilizing Asymmetric Synthesis Technology

Development of scalable active pharmaceutical ingredient processes! We are expanding a comprehensive CDMO business.

In recent years, there have been cases where new compounds with extremely complex chemical structures or compounds with unknown physical property information are considered as candidates for new drugs, and Spira Pharma has seen an increase in requests for the manufacturing development and GMP production of such compounds. In response to the demand for prioritizing development speed, our company is taking on the challenge of process development for manufacturing methods that progress to scale-up, which I believe reflects the high expectations placed on our technical capabilities. How are we tackling the development of manufacturing methods for highly challenging compounds within a strict timeline? We spoke with the chief researcher of the Pharmaceutical Research Headquarters, incorporating examples. As experts in CMC research, our company provides comprehensive support for solving customer challenges, from early-stage R&D to clinical trial drug manufacturing, analysis, application support, and consulting. *For more details on the column, please refer to the related link. For further inquiries, please feel free to contact us.*